Evidence map›Paper›PMID 30395379›Full record

ArticleChembiochem : a European journal of chemical biology2019

Identification of Small-Molecule Modulators of Diguanylate Cyclase by FRET-Based High-Throughput Screening.

Matthias Christen, Cassandra Kamischke, Hemantha D Kulasekara, Kathleen C Olivas, Bridget R Kulasekara, Beat Christen, Toni Kline, Samuel I Miller

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Controlling Biofilm Development Through Cyclic di-GMP Signaling.Advances in experimental medicine and biology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Matthias ChristenEidgenössische Technische Hochschule Zürich, Department of Biology, Auguste-Piccard-Hof 1, 8093, Zürich, Switzerland.ORCID 0000-0001-7724-4562
Cassandra KamischkeUniversity of Washington, Department of Microbiology, 1959 NE Pacific St., Box 357710, Seattle, WA, 98195, USA.
Hemantha D KulasekaraUniversity of Washington, Department of Microbiology, 1959 NE Pacific St., Box 357710, Seattle, WA, 98195, USA.
Kathleen C OlivasSeattle Genetics, Inc., 21823 30th Drive SE, Bothell, WA, 98021, USA.
Bridget R KulasekaraUniversity of Washington, Department of Genome Sciences, 1959 NE Pacific St., Box 357710, Seattle, WA, 98195, USA.
Beat ChristenEidgenössische Technische Hochschule Zürich, Department of Biology, Otto-Stern-Weg-3, 8093, Zürich, Switzerland.
Toni KlineSutro Biopharma, 310 Utah Avenue, Suite 150, San Francisco, CA, 94080, USA.
Samuel I MillerUniversity of Washington, Department of Microbiology, 1959 NE Pacific St., Box 357710, Seattle, WA, 98195, USA.
University of Washington · USBoard of the Swiss Federal Institutes of Technology · CHSeagen (United States) · USSeattle Pacific University · USSutro Biopharma (United States) · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WHELAN, SEAN PJ · 2003 to 2013
$113.7M
Variation in Human Innate ImmunityU54AI057141 · NIAID · UNIVERSITY OF WASHINGTON · PI MILLER, SAMUEL I · 2003 to 2013
$102.3M
Assay Development for High Throughput Molecular ScreeningR21NS067579 · NINDS · UNIVERSITY OF WASHINGTON · PI MILLER, SAMUEL I · 2009 to 2009
$156k
NIAID NIH HHS U54 AI057141NIAID NIH HHS U54 AI057159NINDS NIH HHS R21 NS067579
6 · The paper itself

Abstract

The bacterial second messenger cyclic diguanosine monophosphate (c-di-GMP) is a key regulator of cellular motility, the cell cycle, and biofilm formation with its resultant antibiotic tolerance, which can make chronic infections difficult to treat. Therefore, diguanylate cyclases, which regulate the spatiotemporal production of c-di-GMP, might be attractive drug targets for control of biofilm formation that is part of chronic infections. We present a FRET-based biochemical high-throughput screening approach coupled with detailed structure-activity studies to identify synthetic small-molecule modulators of the diguanylate cyclase DgcA from Caulobacter crescentus. We identified a set of seven small molecules that regulate DgcA enzymatic activity in the low-micromolar range. Subsequent structure-activity studies on selected scaffolds revealed a remarkable diversity of modulatory behavior, including slight chemical substitutions that reverse the effects from allosteric enzyme inhibition to activation. The compounds identified represent new chemotypes and are potentially developable into chemical genetic tools for the dissection of c-di-GMP signaling networks and alteration of c-di-GMP-associated phenotypes. In sum, our studies underline the importance of detailed mechanism-of-action studies for inhibitors of c-di-GMP signaling and demonstrate the complex interplay between synthetic small molecules and the regulatory mechanisms that control the activity of diguanylate cyclases.

Indexed as

Allosteric RegulationCaulobacter crescentusDose-Response Relationship, DrugEnzyme InhibitorsEscherichia coli ProteinsMolecular StructurePhosphorus-Oxygen LyasesSmall Molecule LibrariesStructure-Activity Relationshipdiguanylate cyclaseEnzyme InhibitorsEscherichia coli ProteinsPhosphorus-Oxygen LyasesSmall Molecule Librariesc-di-GMPdiguanylate cyclase inhibitorsFREThigh-throughput screeningstructure-activity relationships

Identifiers

PMID30395379
PMCPMC6509406
OpenAlexW2889204941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.